 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Patients with TTP may have easy bruising, rashes with many little dots or large purple patches (purpura), fever, belly pain, thrombi in the brain or kidneys, or bleeding due to few platelets. Treatments include plasma exchanges to help rid the body of antibodies, removal of the spleen to reduce excess destruction of platelets, and drugs that suppress autoimmune processes. However, some patients have refractory TTP despite standard treatments. Whether intensive immunotherapy aimed at markedly suppressing antibodies against ADAMTS13 will help them is not known.
SUMMARIES FOR PATIENTS
Treatment of Refractory Thrombotic Thrombocytopenic Purpura
21 January 2003 | Volume 138 Issue 2 | Page I-38
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab." It is in the 21 January 2003 issue of Annals of Internal Medicine (volume 138, pages 105-108). The authors are X Zheng, AM Pallera, LT Goodnough, JE Sadler, and MA Blinder.
What is the problem and what is known about it so far?
Thrombotic thrombocytopenic purpura (TTP) is an uncommon but serious disease that can be fatal. Patients with TTP have low numbers of platelets (thrombocytopenia), abnormal red cells, and a tendency to develop tiny clots (thrombi) in small blood vessels. In some adults, TTP is caused by an immune reaction. Their bodies make an antibody that inactivates an important protein (ADAMTS13) whose function is to prevent platelets from sticking together and plugging blood vessels.
Why did the researchers do this particular study?
To see whether intensive immunotherapy works for refractory TTP.
Who was studied?
A 42-year-old woman with chronic relapsing TTP despite many treatments.
How was the study done?
The patient was treated with traditional therapies, including plasma exchange, removal of the spleen, and some immunotherapy (prednisone, vincristine, cyclosporine) for 19 months. She had many relapses despite treatment. Over the following year, the researchers twice treated relapses with powerful intensive immunotherapy administered through the patient's veins (rituximab or rituximab plus cyclophosphamide). The researchers repeatedly measured levels of ADAMTS13 and tested for inhibitors of ADAMTS13.
What did the researchers find?
After the second course of intensive immunotherapy, the patient had no symptoms of TTP and had normal numbers of platelets. Levels of ADAMTS13, which had been low to nonexistent before intensive immunotherapy, normalized. An IgG inhibitor, which had been present before intensive immunotherapy, was no longer detectable. The patient has not needed any additional therapy for 6 months.
What were the limitations of the study?
The study involved one patient and did not directly compare benefits of intensive immunotherapy with standard therapy.
What are the implications of the study?
Intensive immunotherapy may be a promising therapy for adults with refractory TTP. However, we need observations in many more patients and results from controlled studies that directly compare it with other therapies before we routinely recommend it.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Z. Tao, Y. Peng, L. Nolasco, S. Cal, C. Lopez-Otin, R. Li, J. L. Moake, J. A. Lopez, and J.-f. Dong Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions Blood, December 15, 2005; 106(13): 4139 - 4145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fakhouri, J.-P. Vernant, A. Veyradier, M. Wolf, G. Kaplanski, R. Binaut, M. Rieger, F. Scheiflinger, P. Poullin, B. Deroure, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases Blood, September 15, 2005; 106(6): 1932 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Heemskerk, N. Scott-Douglas, S. Yilmaz, and K. McLaughlin Resolution of thrombotic microangiopathy following renal transplant Nephrol. Dial. Transplant., March 1, 2005; 20(3): 639 - 641. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Linenberger and T. H. Price Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications J Intensive Care Med, March 1, 2005; 20(2): 88 - 103. [Abstract] [PDF]
|
|
|
|
|
|
G. Wolf Not known from ADAM(TS-13)--novel insights into the pathophysiology of thrombotic microangiopathies Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1687 - 1693. [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, M. Brunetti, E. Stipa, and S. Amadori Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia Blood, June 15, 2004; 103(12): 4424 - 4428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. L. Zheng, R. M. Kaufman, L. T. Goodnough, and J. E. Sadler Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura Blood, June 1, 2004; 103(11): 4043 - 4049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fakhouri, L. Teixeira, R. Delarue, J.-P. Grunfeld, and A. Veyradier Responsiveness of Thrombotic Thrombocytopenic Purpura to Rituximab and Cyclophosphamide Ann Intern Med, February 17, 2004; 140(4): 314 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zheng, K. Nishio, E. M. Majerus, and J. E. Sadler Cleavage of von Willebrand Factor Requires the Spacer Domain of the Metalloprotease ADAMTS13 J. Biol. Chem., August 8, 2003; 278(32): 30136 - 30141. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
